Dare Bioscience (NASDAQ: DARE) and PLx Pharma (NASDAQ:PLXP) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Analyst Ratings

How to Become a New Pot Stock Millionaire

This is a summary of current ratings and target prices for Dare Bioscience and PLx Pharma, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dare Bioscience 0 0 0 0 N/A
PLx Pharma 0 0 2 0 3.00

PLx Pharma has a consensus price target of $14.00, suggesting a potential upside of 124.00%. Given PLx Pharma’s higher possible upside, analysts plainly believe PLx Pharma is more favorable than Dare Bioscience.

Profitability

This table compares Dare Bioscience and PLx Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dare Bioscience N/A -228.18% -126.97%
PLx Pharma N/A -154.79% -86.47%

Earnings & Valuation

This table compares Dare Bioscience and PLx Pharma’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dare Bioscience $760,000.00 7.80 -$39.30 million N/A N/A
PLx Pharma N/A N/A -$21.32 million N/A N/A

PLx Pharma has lower revenue, but higher earnings than Dare Bioscience.

Insider and Institutional Ownership

8.0% of Dare Bioscience shares are owned by institutional investors. Comparatively, 25.0% of PLx Pharma shares are owned by institutional investors. 28.6% of Dare Bioscience shares are owned by insiders. Comparatively, 47.7% of PLx Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Dare Bioscience has a beta of 2.69, meaning that its share price is 169% more volatile than the S&P 500. Comparatively, PLx Pharma has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.

Summary

PLx Pharma beats Dare Bioscience on 7 of the 9 factors compared between the two stocks.

About Dare Bioscience

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.

About PLx Pharma

PLx Pharma Inc., formerly Dipexium Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen. PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. The Company’s lead product Aspertec 325 mg is a liquid-fill aspirin capsule for prevention of cardiovascular disease. Through PLxGuard delivery system the Company creates a lipid-based formulation of ibuprofen, PL1200 Ibuprofen Capsules, 200 mg.

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.